Market Flux Event

FDA Approves Two Rare Disease Drugs From Sanofi and Regeneron on the Same Day

Read this in the Market Flux app

The US Food and Drug Administration approved two treatments for rare neurological conditions on November 18, clearing Sanofi's Infilbray and Regeneron's Livsayis on the same day.

Sanofi's Infilbray, the brand name for the oral drug venglustat, became the first medicine approved in the United States specifically to treat the neurological manifestations of Type 3 Gaucher disease, a rare lysosomal storage disorder affecting the brain and nervous system. The FDA granted the approval ahead of its November 25 target action date, covering adults and children weighing at least 15 kilograms. The decision rested on a late-stage study of 43 patients aged 12 and older. Venglustat is a glucosylceramide synthase inhibitor that the FDA had placed under priority review following an application accepted earlier in 2026.

Separately, Regeneron received FDA approval for Livsayis, its treatment for generalized myasthenia gravis, a chronic autoimmune muscular disorder. Regeneron had used a Priority Review Voucher to accelerate the FDA's evaluation of the drug, which is also known as cemdisiran, a C5 RNAi therapy for adult patients. The European Medicines Agency had accepted a parallel application for the same drug.

The two approvals arrived on the same day and each addressed a condition with limited prior treatment options, extending the reach of both companies into specialty rare-disease markets.

© AI-generated summary is provided by Market Flux

Sources

  1. Seeking AlphaSanofi wins approval of venglustat for Gaucher disease
  2. ReutersUS FDA approves Regeneron's drug for generalized myasthenia gravis
  3. PiQMarketsFDA approves Sanofi's Infilbray, first drug for type 3 Gaucher disease The US FDA on November 18 approved Sanofi's oral drug venglustat, branded Infilbray, as the first treatment for type 3 Gaucher disease, a rare genetic condition affecting the brain and nervous system. The approval covers adults and children weighing at least 15 kilograms and rests on a late-stage study of 43 patients aged 12 and older.